Similar articles

• Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.

  Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I. Fargeot P, et al. J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505276 Clinical Trial.
• [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].

  Miyauchi M, Yamamoto N, Nakajima N, Suzuki M, Takahashi M, Ohno K, Ogawa K, Tsukamoto T, Yamamoto K, Oheda Y; Chiba Epirubicin Cooperative Study Group. Miyauchi M, et al. Gan To Kagaku Ryoho. 2001 Jan;28(1):43-8. Gan To Kagaku Ryoho. 2001. PMID: 11201379 Clinical Trial. Japanese.
• Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

  International Breast Cancer Study Group; Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A. International Breast Cancer Study Group, et al. J Clin Oncol. 2006 Jan 20;24(3):370-8. doi: 10.1200/JCO.2005.03.5196. J Clin Oncol. 2006. PMID: 16421418 Clinical Trial.
• Systemic (adjuvant) treatment of primary breast cancer.

  Somani N. Somani N. J Assoc Physicians India. 2001 Apr;49:451-3. J Assoc Physicians India. 2001. PMID: 11762618 Review.
• The effects of tamoxifen on the female genital tract.

  Senkus-Konefka E, Konefka T, Jassem J. Senkus-Konefka E, et al. Cancer Treat Rev. 2004 May;30(3):291-301. doi: 10.1016/j.ctrv.2003.09.004. Cancer Treat Rev. 2004. PMID: 15059652 Review.